Aripiprazole: Pharmacology, efficacy, safety and tolerability

Expert Review of Neurotherapeutics

Volumn 5, Issue 3, 2005, Pages 297-307

  Kinghorn, Warren A ^b   McEvoy, Joseph P ^a,b  

^a John Umstead Hospital   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antipsychotic medication; Aripiprazole; Bipolar mania; Schizoaffective disorder; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LITHIUM; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

AGITATION; AKATHISIA; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INVOLUNTARY MOVEMENT; MAINTENANCE THERAPY; META ANALYSIS; METABOLIC SYNDROME X; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; OBESITY; OBSESSIVE COMPULSIVE DISORDER; OSSIFICATION; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; VOMITING; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 18944362633     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.3.297     Document Type: Review

References (82)

1. Oshiro Y, Saw S, Kurahashi N, Tanaka T. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolone derivatives. J. Med. Chem. 41, 658-667 (1998).
2. Kikuchi T, Tottori K, Uwahodo Y et al. 7-{4-[4-(2,3-dichlorophenyl)-1- piperazinyl]butyloxy} -3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exf. Ther. 274, 329-336 (1995).
3. Yamada S, Harano M, Yokoo H, Tanaka M. Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices. J. Pharm. Pharmacol. 49, 206-208 (1997).
4. Aihara K, Shimada J, Miwa T et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenyl cyclase activity and prolactin release. Brain Res. 1003, 9-17 (2004).
5. Lawler CP, Prioleau C, Lewis MM, Mak C. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20(6), 612-627 (1999).
6. Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology 146, 139-143 (1999).
7. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381-389 (2002).
8. Nakai S, Hirose T, Uwahodo Y et al. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur. J. Psychopharmacol. 472, 89-97 (2003).
9. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277, 137-143 (1996).
10. Yokoi F, Grunder G, Biziere K et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27(2), 248-259 (2002).
11. Jordan S, Koprivica V, Chen R et al. The antipsychotic aripiprazole is a potent, partial agonist at the 5-HT1A receptor. Eur. J. Psychopharmacol. 441, 137-140 (2002).
12. Marona-Lewicka D, Nichols DE. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY-293284 in the drug discrimination assay in rats. Psychopharmacology 472, 415-421 (2004).
13. Jordan S, Tadori Y, McQuade RD, Yocca F, Kikuchi T. Definitive evidence that aripiprazole is a D2 and 5HT 1A partial agonist [NR565]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
14. Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacolagy 28, 1400-1411 (2003). Comprehensive review of the in vitro pharmacodynamic activity of aripiprazole.
15. DeLeon A, Patel NC, Crismon ML. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26(5), 649-666 (2004). Comprehensive clinical review of aripiprazole.
16. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1: 'Goldilocks' actions at dopamine receptors. J. Clin. Psychiatry 62(11), 841-842 (2001).
17. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotics: occupancy is not just antagonism. Arch. Gen. Psychiatry 60, 974-977 (2003).
18. Vachharajani N, Vanderslice T, Kollia G et al. Unavailability of an oral solution of the antipsychotic aripiprazole ([2004]NR608). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
19. Boulton D, Dressler D, Lullia G et al. An orally-disintegrating tablet formulation or the antipsychotic aripiprazole ([2004]NR606). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
20. Daniel DG, Stock EG, Wilber CH et al. Intramuscular aripiprazole in acutely agitated psychotic patients ([2004NR612). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
21. Modell S, Daniel D, Stock E et al. Intramuscular aripiprazole treatment for acute agitation in patients with psychosis. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S416 (2004).
22. Mallikaarjun S, Salazar DE, Bramer SL. Time of dosing and food effects on aripiprazole pharmacokinetics [NR564]. Presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
23. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. 44, 179-187 (2004).
24. Bramer SL, Shoaf S, Salazar DE, Mallikaarjan S. Renal and hepatic impairment of the pharmacokinetics of aripiprazole [NR548]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
25. Citrome L, Josiassen R, Bark N, Brown KS, Mallikaarjun S, Salazar DE. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S187 (2002).
26. DelBello MP, Barzman DH, Kowatch RA et al. Aripiprazole for pediatric bipolar disorder: a retrospective chart review ([2004]NK137).Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
27. Streim JE, Breder C, Swanink R et al. Flexible-dose aripiprazole in psychosis of Alzheimer's dementia ([2004]NR385). Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
28. De Deyn PP, Jeste DV, Auby P et al. Aripiprazole for psychosis of Alzheimer's disease [NR363]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA May 17-22 (2003).
29. Breder C, Swanink R, Marcus RN, Kostic S. Dose-ranging study of aripiprazole in patients with Alzheimer's dementia ([2004]NR645). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
30. Goforth HW, Rao M, Sucholeiki R. Chronic interictal psychosis responsive to aripiprazole. J. Clin. Psychopharmacol. 24(5), 573-574 (2004).
31. Staller JA. Aripiprazole in an adult with Asperger disorder. Ann. Pharmacother. 37, 1628-1631 (2003).
32. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can. J. Psychiatry 48(11), 771-772 (2003).
33. Myers WC, Ruiz R. Aripiprazole and psychotherapy for delusional disorder, erotomanic type. J. Am. Acad. Child Adolesc. Psychiatry 43(9), 1069-1070 (2004).
34. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60, 681-690 (2003).
35. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63(9), 763-771 (2002).
36. Petrie JL, Saha AR, McEvoy JR Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result. Eur. Neuropsychopharmacol. 7(Suppl. 2), S227 (1997).
37. Daniel DG, Saha AR, Ingenito G et al. Aripiprazole, a novel antipsychotic: overview of a Phase II study result. Int. J. Neuropsychopharmacol. 3(Suppl. 1), S157 (2000).
38. Cited in: DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26, 649-666 (2004).
39. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6, 325-337 (2003).
40. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64, 1048-1056 (2003).
41. Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 166, 391-399 (2003).
42. Gismondi R, Meltzer HY, Kujawa M et al. Aripiprazole versus perhenazine in treatment-resistant schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S416 (2004).
43. Kane JM, Carson WH, Kujawa MJ et al. Aripiprazole versus perphenazine in treatment-resistant schizophrenia [NR537]. Poster presented at: 156th AnnualMeeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
44. Tandon R, Stock EG, Riera L et al. A naturalistic trial with aripiprazole in a general psychiatric setting ([2004]NR603). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
45. Stock EG, Archibald DG, Tourkodimitris S et al. Long-term effects of aripiprazole on affective symptoms of schizophrenia [NR558]. Presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
46. Immaculada O, Stock E, Archibald D et al. Long-term effects of aripiprazole on affective symptoms of schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S417 (2004).
47. Marder S, Archibald D, Manos G et al Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S243 (2004).
48. Dillenschneider A, Marcus R, Kostic D et al. Short- and long-term effects of aripiprazole treatment on the excitement/hostility symptoms of schizophrenia. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S243 (2004).
49. Carson WH, Archibald DG, Manos G, Marcus RN, Kostic D, Stock EG. Short-term efficacy of aripiprazole on depression and anxiety in schizophrenia ([2004]NR549). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
50. Jody D, Tandon R, Stock E et al. A naturalistic study of aripiprazole treatment in a general psychiatric setting. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S242 (2004).
51. Keck PE, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160, 1651-1658 (2003).
52. Sachs GS, Sanchez R, Marcus RN et al. Aripiprazole versus placebo in patients with an acute manic or mixed episode ([2004]NR742). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
53. McQuade RD, Sanchez R, Carson WH et al. Efficacy of aripiprazole versus placebo in acute mania: pooled analysis ([2004]NR795). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
54. Jody D, McQuade RD, Carson WH et al. Efficacy of aripiprazole in subpopulations of bipolar disorder ([2004]NR811). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
55. Keck PE, Sanchez R, Marcus RN et al. Aripiprazole for relapse prevention in bipolar disorder in a 26-week trial ([2004]NR746). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
56. Sanchez R, Bourin MS, Auby P et al. Aripiprazole vs. haloperidol for maintained treatment effect in acute mania. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S243 (2004).
57. Bilal LA, Patkar AA, Mattila-Evenden M, Peindl KS, Stein-Marcus K, Masand PS. Aripiprazole as an augmentation agent in treatment-resistant depression ([2004]NRI36). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
58. Worthington JW, Fava M, Hughes ME et al. Aripiprazole as an augmentor of SSRIs in mood and anxiety disorder patients [NR196]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
59. Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 1347-1348 (2004).
60. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry 16, 189-194 (2004).
61. Connor DM, Payne VM, Gadde KM et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J. Clin. Psychiatry 66(1), 49-51 (2005).
62. Marcus RN, Carson WH, McQuade RD et al. Overview of safety and tolerability of aripiprazole in acute mania ([2004]NR796). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
63. Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res. 61, 123-136 (2003).
64. Jody D, Saha AR, Iwamoto T, Biswas D. Meta-analysis of weight effects with aripiprazole. Int. J. Neuropsychopharmacol. 5(Suppl. 1), 5186 (2002).
65. Kujawa M, McQuade R, Jody D, Carson W Long-term weight effects of aripiprazole versus olanzapine in a 26-week double-blind study. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S234 (2004).
66. Carson W, Saha AR, Iwamoto T, Lin C, Kujawa MJ. Meta-analysis of prolactin effects with aripiprazole. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S186 (2002).
67. Stock E, Saha AR, Brunell R, Archibald DG, Iwamoto T, McQuade RD. Meta-analysis of cardiac safety with aripiprazole. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S186 (2002).
68. Saha A, Ali MW, Ingenito GG, Wilber R, Luo X, Bramer S. Safety and tolerability of aripiprazole at doses higher than 30 mg. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S185 (2002).
69. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann. Pharmacother. 38, 1265-1271 (2004).
70. Lawson WB, Carson WH, Lam S, Abou-Gharbia N, Marcus RN, Kaplita S. Safety of aripiprazole in patients with schizophrenia grouped by race [NR 577]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
71. L'Italien G, Tandon R, Han J, Li H, Ray S, Carson W. Schizophrenic patients show improved overall effectiveness with aripiprazole treatment compared to atypical antipsychotics. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S417 (2004).
72. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596-601 (2004).
73. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Res. 70, 1-17 (2004).
74. Casey DE, L'Italien GJ, Cislo P. Incidence of metabolic syndrome in olanzapine and aripiprazole patients ([2004]NR338). Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
75. McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65(Suppl. 18), 47-56 (2004).
76. Casey DE, L'Italien G, Waldeck R, Cislo P, Carson WH. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo [NR733]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
77. Litman RE, Maiorca M, Courage E, Collin C. BMI glucose lipids in patients with schizophrenia before and after aripiprazole ([2004]NR599). Poster presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
78. Littrell KH, Petty RG, Hilligoss NM, Kirshner C, Johnson CG. The effect of aripiprazole on insulin resistance in schizophrenia ([2004]NR602). Presented at: 157th Annual Meeting of the American Psychiatric Association, NY, USA, May 1-6 (2004).
79. Casey D, Stock E, Jody D et al. Long-term treatment with aripiprazole: effects on plasma lipid levels and glycaemic control. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S417 (2004).
80. Weiden PJ, Waldeck R, Tafesse E, Cislo P, L'Italien G, Carson WH. Aripiprazole is not associated with increased diabetes risk: a long-term model [NR738]. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, CA, USA, May 17-22 (2003).
81. Blonde L, L'Italien G, Hardy S, Archibald D, Carson W. Pooled randomized schizophrenia trials show greater long-term diabetes risk with olanzapine than aripiprazole treatment. Int. J. Neuropsychopharmacol. 7(Suppl. 2), S242 (2004).
82. Stroup TS, McEvoy JP, Swartz MS et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bull. 29(1), 15-31 (2003).